Patents Examined by Rebecca L. Anderson
  • Inhibitors of protein arginine deiminases
    Patent number: 11453676
    Abstract: Provided herein are inhibitors of protein arginine deiminases (PADs), pharmaceutical compositions comprising said the compounds, and methods for using the compounds for the treatment of diseases.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: September 27, 2022
    Assignee: FORWARD THERAPEUTICS, INC.
    Inventor: Toufike Kanouni
  • Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators
    Patent number: 11453679
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Thomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • Pharmaceutical compounds for treatment of medical disorders
    Patent number: 11447465
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: September 20, 2022
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
    Patent number: 11447510
    Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. Move particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: September 20, 2022
    Assignee: COMPASS PATHFINDER LIMITED
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
  • Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
    Patent number: 11440904
    Abstract: The invention provide novel pyrimidine derivatives and analogs having inhibitory activities towards certain tyrosine kinases, e.g., Bruton's tyrosine kinase (Btk) and/or Focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK), pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by such by tyrosine kinases, e.g., cancers, tumors, fibrosis, inflammatory diseases, autoimmune diseases, diabetes, or immunologically mediated diseases.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 13, 2022
    Inventor: Zhihong Chen
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 11434233
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 6, 2022
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Suyambu Kesava Vijayan Ramaswamy, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Processes for preparing a diaminopyrimidine derivative or acid addition salt thereof
    Patent number: 11434224
    Abstract: Provided are a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist, crystalline forms of a hydrochloride of the diaminopyrimidine derivative, and processes for preparing the same.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 6, 2022
    Assignee: YUHAN CORPORATION
    Inventors: Ja-Heouk Khoo, Doo-Byung Lee, Jun-Sup Lee, Hyun Ju, Woo-Seob Shin
  • Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
    Patent number: 11434200
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 6, 2022
    Assignee: Novartis AG
    Inventors: Lianfeng Huang, Daozhong Zou
  • Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
    Patent number: 11427604
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: August 30, 2022
    Assignee: Mindset Pharma Inc.
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • Inhibiting agents for Bruton's tyrosine kinase
    Patent number: 11427577
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: August 30, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • 1,2,4-oxadiazole derivatives as liver X receptor agonists
    Patent number: 11427586
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 30, 2022
    Assignee: NOVARTIS AG
    Inventors: Kelly D. Boss, Yi Fan, Alec Nathanson Flyer, Declan Hardy, Zhihong Huang, Kathryn Taylor Linkens, Jon Christopher Loren, Fupeng Ma, Valentina Molteni, Duncan Shaw, Jeffrey Smith, Catherine Fooks Solovay
  • Amide substituted indole compounds useful as TLR inhibitors
    Patent number: 11420973
    Abstract: N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 23, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Tasir Shamsul Haque, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Rushith Kumar Anumula
  • Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
    Patent number: 11420949
    Abstract: Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein each R and R? pair are independently selected from (i) or (ii); (i) R and R? are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alcohol, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, and substituted or unsubstituted heteroaryl, or (ii) R and R? together form a substituted or unsubstituted heterocyclic ring structure, or a substituted or unsubstituted heteroaryl ring structure; X is hydrogen, or an alkyl; and Y is O or S.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: August 23, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventor: Longqin Hu
  • Adducts formed from primary amines, dicarbonyl derivatives, inorganic oxide hydroxydes and sp-hybridized carbon allotropes
    Patent number: 11414383
    Abstract: Adducts are described, obtainable from the reaction product of a secondary amine and a diketone, with carbon allotropes in which the carbon is sp2 hybridized, such as graphene, graphite, fullerene, carbon nanotubes and the like, and an inorganic oxide-hy-droxide. A process for preparing said adducts is also described.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 16, 2022
    Assignees: PIRELLI TYRE S.p.A., POLITECNICO DI MILANO
    Inventors: Maurizio Stefano Galimberti, Vincenzina Barbera
  • Compound and pharmaceutical composition comprising same
    Patent number: 11407744
    Abstract: The present disclosure relates to a novel compound and a pharmaceutical composition comprising the same. The compound according to the present disclosure has effects for activating autophagy, and thus can be valuably used for preventing or treating diseases associated with autophagy regulation.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 9, 2022
    Assignee: AUTOPHAGYSCIENCES INC.
    Inventors: Jung Ju Kim, Seong-Won Song, Hye Jeong Shin, Hyeongwan Choi
  • CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 11400097
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 2, 2022
    Assignee: MEI Pharma, Inc.
    Inventors: S. David Brown, David J. Matthews
  • Spiropyrrolidine derived antiviral agents
    Patent number: 11384090
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: July 12, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or
  • Crystal forms and production methods thereof
    Patent number: 11370753
    Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
  • Compound and organic light emitting device comprising the same
    Patent number: 11370782
    Abstract: Provided is a compound of Chemical Formula 1: wherein: each X is independently N or CH, with the proviso that at least one X is N; Y is O or S; L1 and L2 are each independently a single bond, a substituted or unsubstituted C6-60 arylene, or a substituted or unsubstituted C2-60 heteroarylene containing at least one heteroatom selected from the group consisting of N, O, and S; Ar1 and Ar2 are each independently a substituted or unsubstituted C6-60 aryl, or a substituted or unsubstituted C2-60 heteroaryl containing at least one heteroatom selected from the group consisting of N, O, and S; and Ar3 is a substituted or unsubstituted C6-60 aryl, or a substituted or unsubstituted C2-60 heteroaryl containing at least one heteroatom selected from the group consisting of N, O, and S; and to an organic light emitting device including the same.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: June 28, 2022
    Assignee: LG CHEM, LTD.
    Inventors: Min Woo Jung, Dong Hoon Lee, Boon Jae Jang, Jungha Lee, Su Jin Han, Seulchan Park